Hot off the press at NATURE MEDICINE:
Subbiah et al., 2025, Cancer Treatment Paradigms in the Precision Medicine Era.
Find it here (subscription):
https://www.nature.com/articles/s41591-025-03711-w
At Linked In, the prolific Denis Horgan gives a detailed open-access summary of the paper's key points:
It looks like Horgan includes a downloadable version of the 3-page PDF within his Linked In article.
The paper is focused on systematic issues for implementation in the European Union, and one of three key issues is diagnostic fragmentation.
The authors write,
- To fully harness precision medicine and transform cancer care for the better will require a strategic shift to highly personalized interventions that embrace innovation and adaptability....
##
AI CORNER
##
Summarize the several paragraphs about diagnostics.
##
Key Points on Genomics in European Cancer Care – What Needs to Change [Subbiah et al]
-
Start Molecular Testing Early:
The paper urges comprehensive molecular profiling at diagnosis, not just at disease progression. Early testing enables more effective targeted and immunotherapies before tumors evolve resistance, and supports better trial enrollment and long-term tracking. -
Adopt Universal Testing:
For real progress in cancer care, the authors advocate for routine somatic and germline testing in all cancer patients—highlighting the need for investment in infrastructure, cost coverage, and clinical decision tools. -
Support Tumor-Agnostic Therapies:
Europe lags behind the U.S. in approving biomarker-based, tumor-agnostic therapies. The authors call for a strategic framework (like ESMO's ETAC) to evaluate and enable approvals based on molecular alterations rather than tumor histology. -
Coordinate Multi-Stakeholder Action:
Achieving these goals will require coordinated action across regulators, industry, clinicians, and patient groups—particularly to overcome barriers in rare cancers where large RCTs are infeasible.
In sum, the paper pushes for earlier, broader, and smarter molecular diagnostics in cancer care, with updated regulatory and clinical strategies to match.
